Latanoprost/Timolol Teva (Timolol Maleate, Latanoprost)

Latanoprost/Timolol is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family.

• Open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage.
• Ocular hypertension: reduces elevated eye pressure to prevent progression to glaucoma.
• Secondary glaucoma (e.g., pseudoexfoliative): provides pressure control when monotherapy is insufficient.

• Latanoprost binds to prostaglandin F receptors in the ciliary body, increasing uveoscleral outflow of aqueous humor. Timolol maleate non‑selectively blocks β1 and β2 adrenergic receptors in the ciliary epithelium, decreasing aqueous humor production. The combined actions result in a synergistic reduction of intra‑ocular pressure.

The following adverse reactions have been reported with Latanoprost/Timolol eye drops.

Common Side Effects

• Ocular hyperemia: redness of the eye.
• Eye irritation or burning sensation.
• Blurred vision shortly after instillation.
• Increased eyelash growth (hypertrichosis).
• Darkening of the iris color.
• Foreign body sensation.

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, anaphylaxis).
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Marked bradycardia or heart block.
• Bronchospasm or worsening of asthma.
• Systemic beta‑blocker effects such as hypotension.
• Ocular infection or corneal ulceration.

Before prescribing Latanoprost/Timolol, clinicians should consider the following safety measures.

• Cardiovascular assessment: evaluate for bradycardia, heart block, or heart failure.
• Respiratory evaluation: avoid in patients with asthma or severe chronic obstructive pulmonary disease.
• Intra‑ocular pressure monitoring: ensure adequate pressure reduction after initiation.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Storage: Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

• Systemic non‑selective beta‑blockers: additive bradycardia and hypotension.
• Inhaled or oral β‑agonists (e.g., albuterol): may reduce bronchodilator efficacy.
• Other ocular beta‑blockers: risk of excessive intra‑ocular pressure lowering.

Moderate Interactions (Monitor Closely)

• Carbonic anhydrase inhibitors (e.g., dorzolamide): may further lower intra‑ocular pressure.
• Systemic antihypertensives (e.g., calcium channel blockers): monitor for additive blood pressure effects.
• Prostaglandin analogs used concurrently: assess for cumulative ocular surface changes.